Hodgkin lymphomas (HL) and Non-Hodgkin Lymphomas (NHL) represent 13% of total cancer diagnoses in the adolescent and young adult (AYA) population ages 15-39. Even though we continue to learn more and more about the general histological and molecular characteristics of NHL and HL, we are still lacking knowledge based on the unique biology of lymphomas in the AYA population as compared to the better understanding gained in the younger and older populations. To address psychosocial and treatment based issues in this age group it is important to examine the use of age-directed reviews of patients whether this is through retrospective or prospective studies.
Source: Jaglowski S, Linden E, Termuhlen A et al. Lymphoma in Adolescents and Young Adults. Semin Oncol. 2009; 36:381-418.
Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Leuk Res. 2011 Jun;35(6):787-92
Authors: Kita A, Nakahara T, Yamanaka K, Nakano K, Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N, Sasamata M
Abstract
YM155, a novel small-molecule that down-regulates survivin, exhibits broad, potent antitumor activity against a range of human tumors. We evaluated the activity of YM155 in aggressive non-Hodgkin lymphoma. In a number of diffuse...
Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?
J Clin Oncol. 2011 Oct 20;29(30):4045-53
Authors: Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH
Abstract
PURPOSE: Because adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population...
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults.
Nat Rev Clin Oncol. 2011 Jul;8(7):417-24
Authors: Schafer ES, Hunger SP
Abstract
Although the survival rate for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) has steadily improved over the past several decades, it still lags behind that of younger children. This Review explores the reasons for this discrepancy and potential solutions, focusing on patients aged 15-22 years....
Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer.
J Natl Cancer Inst. 2011 Apr 20;103(8):628-35
Authors: Tricoli JV, Seibel NL, Blair DG, Albritton K, Hayes-Lattin B
Each year in the United States, nearly 70 000 individuals between the ages of 15 and 40 years are diagnosed with cancer. Although overall cancer survival rates among pediatric and older adult patients have increased in recent decades, there has been little improvement in...
Malignant hematologic diseases in adolescents and young adults.
Blood. 2011 Jun 2;117(22):5803-15
Authors: Wood WA, Lee SJ
Adolescents and young adults (AYA) with cancer have been designated as a vulnerable population by the National Cancer Institute. This group, defined by the ages of 16-39 years, has not enjoyed the same survival improvements over the past several decades as older and younger cohorts. Several barriers prevent the optimal delivery of oncologic care in this subpopulation. This...
Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study.
J Cancer Surviv. 2011 Jan 28;
Authors: Harlan LC, Lynch CF, Keegan TH, Hamilton AS, Wu XC, Kato I, West MM, Cress RD, Schwartz SM, Smith AW, Deapen D, Stringer SM, Potosky AL,
INTRODUCTION: Cancer is rare in adolescents and young adults (AYA), but these patients have seen little improvement in survival in contrast to most other age groups. Furthermore, participation in research by AYAs is typically low. We...
Socioeconomic Impacts on Survival Differ by Race/Ethnicity among Adolescents and Young Adults with Non-Hodgkin's Lymphoma.
J Cancer Epidemiol. 2010;2010:824691
Authors: Kent EE, Morris RA, Largent JA, Ziogas A, Sender LS, Anton-Culver H
Shorter survival has been associated with low socioeconomic status (SES) among elderly non-Hodgkin's lymphoma (NHL) patients; however it remains unknown whether the same...
Prognostic classification of patients with acute lymphoblastic leukemia by using gene copy number profiles identified from array-based comparative genomic hybridization data.
Leuk Res. 2010 Nov;34(11):1476-82
Authors: Usvasalo A, Elonen E, Saarinen-Pihkala UM, Räty R, Harila-Saari A, Koistinen P, Savolainen ER, Knuutila S, Hollmén J
The development of risk-adapted therapy has improved the treatment results of acute lymphoblastic leukemia (ALL) especially in children. However, more accurate risk...
Review of adherence-related issues in adolescents and young adults with cancer.
J Clin Oncol. 2010 Nov 10;28(32):4800-9
Authors: Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M
This review aims to provide a broad overview of the issues and clinical challenges of nonadherence in adolescents and young adults (AYAs) with cancer. Nonadherence can reduce treatment efficacy, which places the patient at higher risk of relapse, adverse effects, and poor outcomes.
PMID: 20212260 [...
Lymphoma in adolescents and young adults.
Semin Oncol. 2009 Oct;36(5):381-418
Authors: Jaglowski SM, Linden E, Termuhlen AM, Flynn JM
Non-Hodgkin (NHL) and Hodgkin (HL) lymphomas are represented prominently in the adolescent and young adult (AYA) population. These diseases represent 11% of total cancer diagnoses in children, 4% in those 40 years of age and older, and 13% in AYA (aged 15-39 years). Although age-adjusted incidence rates of NHL increase with age, the more aggressive lymphomas are seen...
Acute lymphoblastic leukemia in adolescents and young adults.
Hematol Oncol Clin North Am. 2009 Oct;23(5):1033-42, vi
Authors: Ribera JM, Oriol A
Today, long-term survival is achieved in more than 80% of children 1 to 10 years old with acute lymphoblastic leukemia (ALL). However, cure rates for adults and adolescents and young adults (AYA) with ALL remain relatively low, at only 40% to 50%. Age is a continuous prognostic variable in ALL, with no single age at which prognosis deteriorates markedly....
Challenges in the recruitment of adolescents and young adults to cancer clinical trials.
Cancer. 2007 Dec 1;110(11):2385-93
Authors: Burke ME, Albritton K, Marina N
The adolescent and young adult (AYA) oncology population has seen inferior progress in cancer survival compared with younger children and older adults over the past 25 years. Previously, AYAs had the best survival rates due to the prevalence of highly curable diseases including Hodgkin lymphoma and germ cell tumors, yet today AYAs have...
from patients, caregivers and medical professionals dealing with this disease and many other diseases